Search

Report on first EHA-SWG Scientific Meeting

The meeting was organized with the main support of the EHA in collaboration with the Hematology Unit of G. Gaslini Children’s Hospital and was sponsored by Novartis and Alexion.

Read more

EHA Statement on the Erasmus MC Attack

EHA is deeply saddened and appalled by the news of the twin shootings in Rotterdam, the Netherlands. We condemn these senseless acts of violence in the strongest possible terms.

Read more

EU Parliament agrees on pharmaceutical legislation stance

On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.

Read more

EHA Taskforce on Diversity, Equity, and Inclusion

The Diversity, Equity, and Inclusion Taskforce has a mandate from the EHA Board to develop a policy on Diversity, Equity, and Inclusion that will be the blueprint for:

Initiating and implementing activities to empower underrepresented groups.

Read more

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis

EHA IN COLLABORATION WITH BALTIC SOCIETIES CONCLUDE THE FIRST HYBRID TUTORIAL MEETING IN EHA HISTORY!

 

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis
August 28 – 30, 2020
Virtual & Riga, Latvia 

Meeting Chairs:

Prof S Eichinger (European Hematology Association)
Prof S Lejniece (Latvian Society of…

Read more

Choose your membership

Wherever you are in the world, you can join our vibrant community and benefit from our rigorous resources and career-enhancing opportunities.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more